Our ongoing research explores the mechanisms underlying brain disorders through innovative in vivo and in vitro models. From synaptic plasticity to neuroinflammation and psychedelic therapies, we are advancing biomarker-driven neuroscience.
ONGOING RESEARCH
Driving Innovation in Neuroscience Through Translational & Biomarker Research
Our Commitment
We believe that independent, state-of-the-art research transforms neuroscience drug discovery, laying the groundwork for more targeted, biomarker-driven therapies for brain disorders.
Synaptic Plasticity & Microtubule Dynamics
Deciphering the Link Between Neuronal Structure & Function
Synaptic plasticity, critical for emotions, learning, and memory, is influenced by microtubule dynamics. We investigate:
- Molecular Mechanisms: How tubulin post-translational modifications (PTMs) affect synaptic function.
- Pathologies: The role of microtubule dysfunction in cognitive impairment and neurodegeneration.
- Therapeutic Strategies: Compounds that modulate microtubules to restore synaptic plasticity.
Research in Action
We have developed biomarker assays for microtubule integrity in brain and plasma samples, applying these findings to drug discovery for depression, schizophrenia, and neurodevelopmental disorders.
Interferon-Alpha & Neuroinflammation
A Model for Inflammation-Driven Depression & Cognitive Dysfunction
Interferon-alpha (IFN-α) induces depression-like symptoms, offering a unique model to study immune activation, neuroinflammation, and mood disorders. Our IFN-α Model of Depression replicates:
- Behavioral Outcomes: Depression- and anxiety-like behaviors measured by FST, EPM, and SPT.
- Biomarker Assessment: Levels of BDNF, IL-6, TNF-α, and microtubule markers in brain and plasma.
- Cognitive Impact: Synaptic dysfunction and reduced hippocampal neurogenesis.
Research in Action
We validate classical and novel antidepressants (e.g., SSRIs, ketamine) on IFN-α-induced impairments, paving the way for biomarker-driven patient stratification and targeted anti-inflammatory treatments.
Psychedelics & Neuroplasticity
Unlocking Mechanisms of Psychedelic-Assisted Therapies
Psychedelics such as ketamine and psilocybin exhibit rapid antidepressant and neuroplastic effects. Our research focuses on:
- Pharmaco-EEG & Biomarkers: Measuring brain oscillatory changes and connectivity alterations following psychedelic administration.
- Combined Models: Studying the effects of psychedelics within the IFN-α Model of Depression.
- In Vitro Neuroplasticity: Using human iPSC-derived neurons to assess dendritic growth, synaptic markers, and cytoskeletal dynamics.
Research in Action
Our studies demonstrate rapid increases in synaptic markers and are developing biomarker panels to track neuroplastic changes in both preclinical and clinical settings, refining patient selection for psychedelic-assisted therapy trials.
